Overview

• RNAi therapeutics firm's fiscal Q1 revenue rose but missed analyst expectations

• Company launched first commercial product, REDEMPLO, in the U.S.

• Company closed public offerings raising $930 mln, improving financial position

Outlook

• Arrowhead anticipates REDEMPLO will be marketed independently in Canada later this year

• Company plans to advance RNAi therapeutics for cardiovascular disease and tauopathies

• Arrowhead expects to leverage improved financial position for program advancements

Result Drivers

• REDEMPLO LAUNCH - Arrowhead launched its first commercial product, REDEMPLO, in the U.S. and received regulatory approvals in China and Canada, contributing to revenue growth

• OBESITY PROGRAMS - Encouraging early results from obesity programs, including significant weight loss and fat reduction in trials, were reported

• FINANCIAL POSITION - Arrowhead improved its financial position with $930 mln raised from public offerings and a $200 mln milestone payment from Sarepta Therapeutics

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $81.00, about 19% above its February 4 closing price of $68.06

Press Release: ID:nBw9ZYjda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)